Comprehensive Management of Von Hippel-Lindau Disease: Genetic and Oncological Perspectives

Von Hippel-Lindau disease (VHL) is an inherited disorder that predisposes individuals to specific types of benign tumors, malignant tumors, and cysts in multiple organs, requiring the involvement of genetic counselors and clinicians across the interprofessional team for optimal management. In this enduring webinar, gain expert perspectives from Dr. Eric Jonasch, Professor in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center. Start the activity now.

STATEMENT OF NEED

Von Hippel-Lindau disease (VHL) is an autosomal dominant disease in which germline pathogenic variants in the VHL gene predispose individuals to specific types of benign tumors, malignant tumors, and cysts in multiple organs, including clear cell renal cell carcinoma (RCC), renal cysts, central nervous system hemangioblastomas, retinal hemangioblastomas, pancreatic tumors and cysts, endolymphatic sac tumors, and cystadenomas of the epididymis and broad ligament (NIH, 2024). Clinical manifestations and disease severity vary among individuals, and tumors and cysts can cause increased pain and pressure on surrounding structures as they grow (NORD, 2023). Due to its multisystemic complexity, care of individuals with VHL requires involvement of clinicians across the interprofessional team, including genetic counselors, medical geneticists, general surgeons, urologic oncologists and surgeons, neurologists and neurosurgeons, medical oncologists, ophthalmologists, and endocrinologists (NIH, 2024). Improved understanding of molecular biology, early intervention therapies, and development of targeted systemic therapies are needed in order to optimize the management of VHL in its varying manifestations (NIH, 2024). In this activity, Dr. Eric Jonasch, Professor in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center, will provide genetic and oncological perspectives to inform the comprehensive management of patients with VHL. 

TARGET AUDIENCE

Medical geneticists, genetic counselors, medical oncologists, nurse practitioners, physician associates/assistants, and oncology nurses involved in the treatment of patients with von Hippel-Lindau (VHL) disease.

Upon completion of this activity, participants should be able to

• Recognize the diverse clinical presentations of VHL disease–associated tumors across different organ systems
• Discuss the capabilities and limitations of current genetic testing techniques for VHL disease
• Evaluate the latest evidence on novel and emerging therapies for VHL disease–associated tumors
• Apply expert strategies to clearly communicate complex genetic information to patients and family members during counseling sessions

PROVIDED BY

JOINTLY ACCREDITED PROVIDER

In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS

i3 Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants/Associates

i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 7/30/2025. PAs should only claim credit commensurate with the extent of their participation. 

Nurse Practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Nursing Continuing Professional Development

A maximum of 1.0 ANCC contact hour may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.5 ANCC contact hours of pharmacology credit for Advanced Practice Registered Nurses.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 ANCC contact hour. 

ONCC RECERTIFICATION

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates may apply 1.0 ILNA points toward: 

• Care Continuum (OCN®, CBCN®, CPHON®, AOCNP®)
• Oncology Nursing Practice (OCN®)
• Psychosocial Dimensions of Care (AOCNP®, CPHON®, OCN®, CBCN®)
• Roles of the APRN (AOCNP®)
• Symptom Management, Palliative Care, Supportive Care (OCN®, CPHON®, AOCNP®)

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD/CE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD/CE activity. CME/NCPD/CE activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME/NCPD/CE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Eric Jonasch, MD, discloses that he has served as a consultant for Aveo, Eisai, Exelixis, GlaxoSmithKline, Ipsen, Novartis, Merck, NiKang, Takeda, and Telix; and that he has received grants/research support from Aveo, AbbVie, Bristol Myers Squibb, Corvus, Merck, NiKang, and Telix.

i3 Health has mitigated all relevant financial relationships.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must watch the video and submit a completed evaluation at the end of the activity.

TECHNOLOGY REQUIREMENTS FOR VIRTUAL CME | NCPD | CE ACTIVITIES

For virtual (asynchronous, archived live, home study; synchronous webinars) CME/NCPD/CE activities, include access to system requirements:

• The Internet browser(s) supported and minimum versions of each required by the learner to complete the online activity.
• The minimum memory, storage, processor, and Internet speeds require by the learner to complete the online activity.

UNAPPROVED USE DISCLOSURE

i3 Health requires CME/NCPD/CE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The information provided at this CME/NCPD/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.

COMMERCIAL SUPPORT

This activity is supported by an independent educational grant from Merck Sharp & Dohme LLC.